CPRX Catalyst Pharmaceuticals, Inc.

4.15-0.07 (-1.66%)
IEX real time price: 12:40:56 PM

Quote

Previous Close
$4.22
Day Range
$4.08-$4.28
52 Week Range
$1.85-$6.16
Volume
668,274
Avg Volume
1,327,744
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$426.84M
Enterprise Value (EV)
$380.56M
PE Ratio
-
EV/EBITDA
-10.79
Price/Sales
-
Price/Book
8.55
PEG Ratio
0.18

Financials

Revenue
-
Gross Profit
-
EBITDA
-$35.26M
EPS, ttm
-$0.28
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/5/2019 (18 days)
Debt to Equity
-
Debt
$7.20M
Cash
$53.48M
Net Debt
-

Performance

Beta
1.45
200 Day Moving Avg
$3.42
50 Day Moving Avg
$3.66
52 Week Change
37.01%
YTD Change
98.34%
1 Month Change
12.53%
3 Month Change
-20.53%
6 Month Change
61.07%
1 Year Change
37.01%
2 Year Change
253.18%
5 Year Change
226.74%

Share Count

Shares Outstanding
102.9M
Float
-
Restricted Shares
102.9M
Restricted Shares, %
100.00%

Catalyst Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Other

CEO: Patrick J. McEnany

Website: http://www.catalystpharma.com

Description: Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

Employees: 51